CRN Asks FDA To Stop Enforcement Against Synthetic Botanicals
This article was originally published in The Tan Sheet
Executive Summary
FDA’s position “is neither scientifically justified, logical nor in the interest of the public health,” CRN argues, asking FDA to reverse its position on synthetic botanicals outside the agency’s revision of the NDI draft guidance.
You may also be interested in...
FDA Enforces New Dietary Ingredient Notification Requirement With Import Alerts
Supplement industry stakeholders say FDA is detaining without inspection imported products previously allowed entry, including synthetic botanicals and ingredients it asserts should be covered in NDI notifications. Firms can reduce their vulnerability by reviewing alerts before contracting with suppliers.
FDA Enforces New Dietary Ingredient Notification Requirement With Import Alerts
Supplement industry stakeholders say FDA is detaining without inspection imported products previously allowed entry, including synthetic botanicals and ingredients it asserts should be covered in NDI notifications. Firms can reduce their vulnerability by reviewing alerts before contracting with suppliers.
FDA Enforces New Dietary Ingredient Notification Requirement With Import Alerts
Supplement industry stakeholders say FDA is detaining without inspection imported products previously allowed entry, including synthetic botanicals and ingredients it asserts should be covered in NDI notifications. Firms can reduce their vulnerability by reviewing alerts before contracting with suppliers.